AB1373 PREDICTORS OF RECURRENCE IN PEDIATRIC PATIENTS WITH NON-INFECTIOUS UVEITIS UNDERGOING ADALIMUMAB TAPERING: AN INTERNATIONAL MULTICENTER STUDY

摘要: Background Adalimumab (ADA) is frequently administered to pediatric patients with non-infectious uveitis (NIU). Given safety considerations, the quality of life of children, and cost implications, exploring the possibility of tapering/withdrawing ADA in patients experiencing a prolonged period of persistent remission has been suggested. However, few studies have investigated this in pediatric rheumatology, and none have specifically addressed how to taper/discontinue ADA in children with NIU.Objectives To evaluate factors associated with the risk of NIU relapse in patients undergoing ADA tapering.Methods A multicenter retrospective cohort study involving 18 international tertiary centers was conducted. Patients diagnosed with NIU, with or without an associated systemic disease, before age 18 and treated with ADA were included. ADA was administered subcutaneously every 2 weeks (20 mg for patients < 30 kg …